Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA121-28 in RET Fusion-Positive Advanced NSCLC
NCT05117658Phase 2Unknown
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Feb 2022
- Primary completion
- Oct 2023
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ha121-28 in non-small cell lung cancer (NSCLC), sponsored by CSPC ZhongQi Pharmaceutical Technology. Status: unknown.
02
Drugs
ha121-28
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05117658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05117658.